Programmed cell death protein 1 and Tubulin beta chain (PD-1 / β-tubulin)

The 'PD-1 / β-tubulin' designation refers to a synergistic therapeutic strategy targeting two distinct molecular pathways: the immune checkpoint receptor Programmed cell death protein 1 (PD-1) and the structural protein Tubulin beta chain (β-tubulin). PD-1 is a cell surface receptor on T cells that, when bound by its ligands PD-L1 or PD-L2, suppresses T-cell activation to maintain peripheral tolerance and prevent autoimmunity (UniProt Q15116; PubMed: 22517480). β-tubulin is a major component of microtubules, which are essential for maintaining cell shape, intracellular transport, and forming the mitotic spindle during cell division (UniProt P07437; PubMed: 14707820). In clinical oncology, PD-1 inhibitors like pembrolizumab are frequently combined with tubulin-binding agents such as paclitaxel or docetaxel. This combination is particularly effective because tubulin-disrupting chemotherapy can induce immunogenic cell death, releasing tumor-associated antigens and pro-inflammatory signals that enhance the efficacy of the PD-1 blockade (PubMed: 30280635). This dual-targeting approach is a standard of care for various malignancies, including advanced non-small cell lung cancer and certain types of breast cancer.

Other names

PDCD1CD279SLEB2hPD-1TUBBTUBB5OK/SW-cl.56M40

PD-1 inhibitors block the PD-1/PD-L1 signaling axis to restore T-cell mediated anti-tumor immunity, while beta-tubulin inhibitors disrupt microtubule dynamics to induce mitotic arrest and immunogenic cell death.